1. Introduction {#sec1}
===============

The sudden outbreak of novel coronavirus (SARS-CoV-2) infection emanated from Wuhan, China and spread throughout the world excepting a few countries to date \[[@bib1]\]. The virus is responsible for causing novel disease, which WHO officially called COVID-19. As of April 23, 2020, World Health Organization (WHO) estimated that new coronavirus touched 213 countries, areas or territories \[[@bib2],[@bib3]\]. The infection rate is increasing. However, the fatality rate of SARS-CoV-2 (3.4%) estimated by WHO is lower than previous fatal diseases SARS and MERS, which had 9.6% and 35% death rates, respectively \[[@bib4],[@bib5]\].

Coronaviruses are enveloped, positive single-stranded RNA viruses with large genome size ranging from 26 kb to 32 kb. These viruses are representative of four subfamilies, which include alpha-, beta-, gamma- and delta-coronaviruses. SARS-CoV-2 showed more sequence similarity with SARS-CoV than MERS-CoV when genome sequences of these mentioned viruses were compared \[[@bib6]\]. But they also exhibit dissimilarities that can influence their process of pathogenesis \[[@bib7],[@bib8]\]. SARS-CoV-2 infects humans through the same entry point of the ACE receptor which is expressed in the respiratory tract \[[@bib9],[@bib10]\]. However, among various proteins, four proteins are commonly found in the structure of all coronaviruses representing spike (S), envelope (E), membrane (M), and nucleocapsid (N) \[[@bib8]\]. The initial and important stage of viral entry into host cell is receptor recognition \[[@bib11]\]. The assembly of viral particle involves M protein and E protein, while virus binding and entrance into host cell take place by S protein with the assistance of SARS-CoV-2 angiotensin-converting enzyme \[[@bib10],[@bib12]\].

The coronavirus (SARS-CoV-2) belongs to the family of Beta-coronaviruses, which are responsible for causing severe human respiratory syndrome \[[@bib3],[@bib13]\]. The virus is spread mainly through community transmission, while SARS and MERS affect people via nosocomial spread \[[@bib14]\]. It can transmit from one individual to other by respiratory droplets. SARS-CoV-2 infected patients have general signs and symptoms, suffering initially from common flu-like fever, sputum production, dyspnoea, headache, sore throat/pharyngalgia, and diarrhoea, which may further lead to express life-threatening symptoms including fatal pneumonia \[[@bib15]\]. COVID-19 affected patients, either symptomatic or asymptomatic, were detected with the nose area containing a higher viral load than in throat \[[@bib16]\]. A critically ill patient has a series of complexities with progression of disease.

The efficacy and safety of antivirals require evaluation by clinical trial \[[@bib3]\]. There is no efficient, safe, and specific potential therapeutic to be approved for rapid remedy of this new respiratory syndrome to date \[[@bib17],[@bib18]\]. Clinical trials of some drugs have been started, yet till now, only a few candidates have shown some efficacy in *in vitro* studies \[[@bib19]\]. Not many have progressed to randomized animal or human trials; hence they may have limited use to counter infection \[[@bib19]\]. Many countries and some pharmaceutical companies announced their headway and programs to develop vaccines (e.g. subunit, mRNA, DNA, live-vector vaccine) against the virus. But the developmental process of making human vaccine from concept to licensure may require years \[[@bib20]\]. As the epidemic is still spreading, medicinal plants may be alternatively used in making drugs as early as possible. Several scientific researchers reported the helpfulness of plants due to their medicinal value and therapeutic uses as drugs from the ancient times \[[@bib21]\]. Plant-derived active compounds of different plant parts are useful for treating diseases including diarrhoea, headache, and inflammation, and bacterial and fungal infections. From prehistoric times, traditional people utilized these plants for the remedial purposes of health deteriorating diseases because of the existence of numerous phytochemicals \[[@bib22]\]. Various limitations are associated with modern treatment options including drug-resistance, severe side effects, adverse toxicity profiles, complicated medication etc. Natural products have the potential to form the basis of holistic health care \[[@bib23]\]. The properties of antioxidants render medicinal plants to be effective in treating life-threatening diseases such as cancer, Alzheimer\'s disease, diabetes, malaria, and cardiac diseases ([Table 1](#tbl1){ref-type="table"} ) while minimizing drug toxicity \[[@bib24]\].Table 1List of plant metabolites used in the study with respective source and activities.Table 1MetabolitesPubChem CIDClassSourceActivitiesReferencesAllicin65036S-containing compound*Allium sativum*Antimicrorial, antiviral Antioxidant, anti-cancer activity\[[@bib25]\]Andrographolide5318517Diterpenoid labdane*Andrographis paniculata*antioxidant, anti-inflammatory, and anti-cancer\[[@bib26]\]Apigenin5280443FlavonoidVegetable and fruitEffective in cancer, depression, diabetes & Alzheimer\'s disease,\[[@bib27]\]Asiatic acid119034Aglycone type pentacyclic triterpenoids*Centella asiatica*Antioxidant, cardioprotective, anti-inflammatory, antitumor, neuroprotective, antimicrobial\[[@bib28]\]Avicularin5490064quercetin-3-a-L arabinofuranoside (flavonoid)*Psidium guyava, Lespedeza cuneata*anti-inflammatory, anti-oxidant, hepatoprotective activity\[[@bib29]\]Capsaicin1548943Alkaloid*Capsicum genus*Pruritis, pain relief, non-steroidal anti-inflammatory drug induced gastritis\[[@bib30]\]Chavibetol596375PhenylpropanoidPiper betleimmunomodulatory, radical scavenging\[[@bib31]\]Cinnamic acid444539Aromatic carboxylic acids*Cinnamomum* speciesAntibacterial, antifungal, antimalarial, antitubercular\[[@bib32]\]Curcumin969516Polyphenolic compound*Curcuma longa*antibacterial, anti-inflammatory antiviral, antioxidant, anti-arthritis & anti-cancer activity\[[@bib33]\]Eugenol3314Phenylpropanoid*Ocimum tenuiflorum, Eugenia caryophyllata*antimicrobial, anti-inflammatory, analgesic and antioxidant\[[@bib34]\]Arjunone14034821Flavonoids*Terminalia arjuna*Arjunone and other compounds have role in antioxidant, antiatherogenic, anti-inflammatory, anti-carcinogenic activity\[[@bib35]\]Galangin5281616FlavonolHoney, *Alpinia officinarum*, propolisAnti-cancer, anti-mutagenic, anti-oxidative, radical scavenging etc.\[[@bib36]\]Gentisic acid3469Phenolic acid*Gentiana*, *Citrus*, *H. rosa*-sinensis,\
*O. europaea, S. indicum*Antioxidant, neuroprotective, antiinflammatory, hepatoprotective, antimicrobial activities\[[@bib37]\]Guajaverin5481224Flavonoid*Psidium guyava*Anti-plaque activity\[[@bib38]\]Kaempferol5280863Flavonoid aglyconeVegetable and fruitAnti-inflammatory, antioxidant, antimicrobial, antitumor, cardioprotective, and antidiabetic activities\[[@bib39]\]Luteolin5280445FlavonoidCarrots, celery peppers, olive peppermintAnticancer, antioxidant, antimicrobial, anti-inflammatory, and activities\[[@bib40]\]m-Coumaric acid637541Phenolic acid*Solanum nigrum*Role in pharmacological activities\[[@bib41]\]Piperic acid5370536Alkaloid*Piper nigrum*No known function\[[@bib42]\]Piperine638024Alkaloid*Piper* spp.Anticancer, antimicrobial, antimalarial\[[@bib42]\]Quercetine5280343FlavonoidDiverse plant speciesAntioxidant, cardiovascular, antiviral, anti-inflammatory, anticancer, antimicrobial\[[@bib43]\]Swertiamarin442435Secoiridoid glycoside*Swertia chirata*Anti-arthritic, anti-diabetic Cardio-protective, Anticancer, Anti-hepatitis, Antibacterial, anti-atherosclerotic\[[@bib44]\]Swertinin5491517Secoiridoid glycoside*Swertia chirata*Role in pharmacological activities\[[@bib45]\]Thymoquinone10281Monoterpene*Nigella sativa*Anti-oxidant and anti-inflammatory properties, Anti-microbial, Anti-arthritic, anti-cancer efficacy\[[@bib46]\]Vincamine15376Alkaloid*Catharanthus roseus, Vinca minor*Cerebral disorders, antiulcer activity, cerebrovascular insufficiencies\[[@bib47]\]Vitexin5280441Apigenin flavone glucoside*Crataegus species*Anti-inflammatory effects, anti-oxidant effects, anti-carcinogenic effects, anti-viral effects\[[@bib48]\]Withaferin265237Steroidal lactone*Withania somnifera*Anti-cancer, adaptogenic, anti-stress, immunomodulatory, anti-inflammatory, anti-tumor, cardioprotective, and neuroprotective activities.\[[@bib49]\]Zingiberene92776IsoprenoidsZingiber OfficinaleAnti-ulcer, antibacterial, cytoxic effect\[[@bib50]\]

The expansion of natural product as new medicine or drug to resist the emerging virus SARS-CoV-2 could be done to bypass the side effects of synthetic drugs. Therefore, the study aimed at evaluating some plant-based active compound for drug candidacy against SARS-CoV-2 through virtual screening methods and various computational investigations.

2. Material and methods {#sec2}
=======================

2.1. Retrieval of SARS-CoV-2 proteins/protein-domains and plant metabolites {#sec2.1}
---------------------------------------------------------------------------

The 3D structures of SARS-CoV-2 main proteases (6W63, 6LU7), Nsp9 (Non-structural protein-9) RNA binding protein (6W4B), spike receptor binding domain (6M0J), spike ecto-domain (6VYB), and HR2 Domain (6LVN) were retrieved from the RCSB Protein Data Bank \[[@bib51]\]. A total 27 plant metabolites belonging to different classes were extracted from the PubChem database (<https://pubchem.ncbi.nlm.nih.gov/>) in SDS (3D) format ([Table 1](#tbl1){ref-type="table"}) \[[@bib52]\]. The structures were further converted into the PDB format by Open Babel v2.3 \[[@bib53]\].

2.2. Screening of plant metabolites against SARS-CoV-2 proteins/protein-domains {#sec2.2}
-------------------------------------------------------------------------------

Molecular docking is an effective approach for screening suitable therapeutics against specific drug target of deadly pathogens \[[@bib54]\]. This powerful tool is used to model the interaction between small ligands and macromolecules, thereby paving the way for drug discovery \[[@bib55]\]. The binding affinity of 27 plant metabolites with different SARS-CoV-2 proteins/protein domains (drug targets/macromolecules) were determined by using the PatchDock server \[[@bib56]\]. Recently, alpha-ketoamide (CID 6482451) has been suggested as a SARS-CoV-2 MPP inhibitor by experimental study \[[@bib57]\]. The ligand was used as a positive control for the present study, and employed for docking analysis against all six macromolecules. The docked complexes were further refined via the FireDock refinement tool \[[@bib58]\]. The ligand bond complexes were visualized by Discovery Studio v3.1 and PyMOL v2.0 \[[@bib59],[@bib60]\].

2.3. Analysis of drug surface hotspot and ligand binding pocket prediction {#sec2.3}
--------------------------------------------------------------------------

The drug surface hotspot of SARS-CoV-2 proteins was analysed by investigating the docked complexes with the top metabolites using LigPlot+, Discovery Studio and PyMOL v.2.0 software \[[@bib59],[@bib60]\]. Binding patterns of asiatic acid, avicularin, guajaverin, and withaferin with six macromolecules were allowed for comparative structural analysis. Moreover, interaction of Alpha-ketoamide with the studied proteins were also investigated.

2.4. Drug profile analysis of top metabolites {#sec2.4}
---------------------------------------------

Absorption, distribution, metabolism, and excretion (ADME) are four major criteria that influence the drug levels and kinetics of drug exposure to the tissues within an organism. The pharmacological activity and performance of a drug is largely controlled by these parameters \[[@bib61]\]. The SwissADME server was used to assess the ADME properties of top four metabolites \[[@bib62]\]. The BOILED-Egg model was employed to calculate the blood-brain barrier (BBB) in the studied compounds \[[@bib63]\]. The relative toxicity of top drug candidates were analysed via the ProToxII server \[[@bib64]\]. This popular webserver efficiently predicts various toxicity endpoints by incorporating molecular similarity, fragment tendency and fragment similarity methods. The server also predicted the oral toxicity based on the analysis of two-dimensional (2D) similarity to compounds with a known median lethal doses (LD50). The set used for the prediction consists of approximately 38,000 unique compounds with known oral LD50 values measured in rodents \[[@bib65]\]. Additionally, OSIRIS Property Explorer were employed to investigate the undesired effects of these compounds \[[@bib66]\].

2.5. Prediction of drug targets and available drug molecules from DrugBank {#sec2.5}
--------------------------------------------------------------------------

SwissTargetPrediction was utilized to estimate the possible macromolecular targets of predicted drug candidates \[[@bib67]\]. The server predicts based on a combination of 2D and 3D similarity with a library of 370000 known bioactive compounds on approximately 3000 proteins. Moreover, the SwissSimilarity web tools were used to identify potential drug molecules against SARS-CoV-2 based on homology screening of predicted top drug candidates. The server allowed ligand-based virtual screening of several libraries of small molecules to find approved, experimental, or commercially available drugs from DrugBank using different approaches including FP2 fingerprints, electroshape, spectrophores, and align-IT \[[@bib68]\].

3. Results {#sec3}
==========

3.1. Screening of plant metabolites against SARS-CoV-2 {#sec3.1}
------------------------------------------------------

All of the retrieved structures of SARS-CoV-2 proteins/protein-domains (macromolecules) and plant metabolites (ligands) were optimized and employed for molecular docking to predict the affinity between the above-mentioned ligands and the macromolecules. The metabolites were ranked based on global binding energy and the results depict that the top four scorers (metabolites) were the same for each of the macromolecules in terms of minimum binding energy ([Table 2](#tbl2){ref-type="table"} and Supplementary File 1). In each case, asiatic acid, avicularin, guajaverin, and withaferin showed the best binding interactions with six studied macromolecules ([Fig. 1](#fig1){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}). Moreover, asiatic acid exhibited the highest binding affinity with SARS-CoV-2 main protease (−53.05 kcal/mol), Nsp9 RNA binding protein (−50.04 kcal/mol), and spike ecto-domain (60.68 kcal/mol) ([Fig. 2](#fig2){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}), while guajaverin bound with the spike receptor binding domain and HR2 Domain with a binding energy of −47.34 kcal/mol and −28.73 kcal/mol, respectively ([Fig. 3](#fig3){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}).Table 2Analysis of global binding energy and interaction sites of the screened top 4 metabolites.Table 2MacromoleculesLigandsGlobal EnergyACEScoreAreaLigand binding residues6W63α-ketoamide (Control)−56.92−16.844560526.40Asp197, Leu272, Gly275, Leu286, Leu287, Asp289Asiatic acid−53.05−15.264916577.10His41, Met49, Tyr54, Asn142, Met165Avicularin−48.62−18.504694532.10Thr25, Thr26, His41, Cys44, Ser46, Met49, Gly143, Cys145Guajaverin−48.48−15.124450497.50Thr25, His41, Cys44, Met49, Asn142, Cys145, Met165, Asp187, Arg188Withaferin−48.46−14.084984597.40His41, Met49, Met165, Pro168, Ala1916W4Bα-ketoamide (Control)−48.60−16.394458504.60Phe41, Trp54, Ile66, Thr68, Glu69Asiatic acid−50.04−16.374998564.20Met13, Gly39, Arg40, Phe41, Val42, Phe57, Pro58, Ile66Withaferin−47.95−13.304896570.40Arg40, Val42, Phe57, Pro58,Lys59, Ser60, Ile66Guajaverin−42.72−10.634548641.40Asn1, Asn2, Glu3, Gln50, Pro72, Pro73Avicularin−39.83−23.804556514.50Met49, Met165, Glu166, Thr1906VYBα-ketoamide (Control)−63.94−17.325728705.10Thr547, Gly548, Thr549,Asp745, Val976Asiatic acid−60.68−22.336276771.50Phe338, Ala363, Tyr365, Leu368, Cys379, Pro384, Leu387, Leu390, Phe392, Val395, Cys432, Ile434, Leu513, Val524Withaferin−60.19−20.495760793.10Ile410, Pro412, Leu425, Pro426, Cys432, Val433, Phe464, Val512, Leu513Guajaverin−55.24−17.515208659.20Ile410, Pro412, Lys424, Gly431, Cys432, Val433, Val512Avicularin−52.93−17.155474683.30Ala411, Pro412, Leu425, Cys432, Val433, Val5126LVNα-ketoamide (Control)−25.52−2.714318564.20Ile16, Asn20, Lys24, Asn27, Glu28Guajaverin−28.73−2.133696443.50Asp17, Arg18, Glu21, Lys24Withaferin−28.11−1.244376507.70Lys14, Lys24, Arg18Asiatic acid−27.58−1.124366500.30Lys14, Lys24, Asp17, Arg18, Glu21Avicularin−26.48−1.223986465.10Asp17, Arg18, Glu21, Asn206M0Jα-ketoamide (Control)−60.50−9.345374655.40Lys94, Tyr196, Asp206, Glu208, Val209, Asn210Guajaverin−47.34−11.224554575.60Leu95, Gln98, Ala99, Glu208, Asn210, Ala396, Lys562, Trp566Withaferin−46.84−11.135598640.50Leu95, Gln98, His195, Tyr196, Lys562Asiatic acid−45.69−13.095978691.70Leu95, Gln98, Ala99, Tyr202, Asp206, Glu208, Val209, Ala396, Lys562, Pro565, Trp566Avicularin−43.13−11.095232604.20Lys94, Leu95, Tyr196, Val209, Asn210, Ala396, Lys5626LU7α-ketoamide (Control)−56.13−15.074578492.00Asp197, Lys236, Tyr237, Leu272Avicularin−54.04−14.774584520.60His41, Met49, His164, Met165, Glu166, Pro168, Thr190, Asp187, Arg188, Gln189Guajaverin−51.69−12.924182515.50Met49, Phe140, His163, His164, Met165, Glu166, Arg188, Gln192Withaferin−47.08−14.064708560.60Thr24, Met49, His41, Cys145, Met165, Arg188Asiatic acid−43.52−13.905050562.20Met49, Leu141, Asn142, Ser144, Cys145, His163, Glu166Fig. 1Chemical structures of asiatic acid (A), guajaverin (B), avicularin (C) and withaferin (D).Fig. 1Fig. 2Molecular interaction of asiatic acid with SARS-CoV-2 main protease (A), Nsp9 RNA binding protein (B), and spike ecto-domain (C).Fig. 2Fig. 3Molecular interaction of SARS-CoV-2 main protease with avicularin (A), HR2 domain with guajaverin (B), and spike receptor-binding domain with guajaverin (C).Fig. 3

3.2. Analysis of drug surface hotspot and ligand binding pocket prediction {#sec3.2}
--------------------------------------------------------------------------

The structural conformation of the docked complex was analysed to unravel the drug surface hotspot of studied SARS-CoV-2 proteins. The ligand binding pattern and interacting residues with their respective positions were investigated ([Table 2](#tbl2){ref-type="table"}). Results revealed that the amino acids from 41 to 54 and 142--190 positions were crucial for the binding interactions of SARS-CoV-2 main protease protein (6W63). Moreover, His41, Cys44, Met49, Asn142, Cys145, Met165 were involved in maximum cases to form the docked complexes. The ligands showed highest binding affinity for 39--73 and 142--166 regions of Nsp9 RNA binding protein (6W4B). Again, the residues from 94 to 99 and 563--566 regions were identified as top surface hotspots for spike receptor binding domain (6M0J) where the position Lys94, Leu95, Tyr196, Lys562, Trp566 were most dominant ([Table 2](#tbl2){ref-type="table"}).

3.3. ADME analysis of top drug candidates {#sec3.3}
-----------------------------------------

Different ADME properties, i.e., physicochemical parameters, pharmacokinetics, lipophilicity, water solubility, medicinal chemistry of top drug candidates were estimated to evaluate their drug profiles ([Fig. 4](#fig4){ref-type="fig"} and [Table 3](#tbl3){ref-type="table"} ). Analysis of inhibition effects with different CYP isoforms (CYP1A2, CYP2D6, CYP2C9, CYP2C19, CYP3A4) revealed that none of the candidates had such an interaction possibility with any cytochromes P450 isoforms. GI absorption was found higher for asiatic acid and withaferin, while lower for guajaverin and avicularin. Moreover, blood-brain barrier (BBB) permeation was calculated by the BOILED-Egg model, which revealed no BBB permeant among the studied top drug candidates. Each candidate was water soluble from a moderate to high level, while guajaverin and avicularin showed maximum solubility ([Table 3](#tbl3){ref-type="table"}).Fig. 4ADME analysis of top four metabolites; A: Asiatic acid, B: Guajaverin, C: Avicularin, and D: Withaferin.Fig. 4Table 3Drug profile and ADME analysis of the top four metabolites.Table 3ParameterTop Main Protease Protein Inhibitors of SARS-CoV-2Asiatic acidGuajaverinAvicularinWithaferin**Physicochemical parameters**FormulaC30H48O5C20H18O11C20H18O11C28H38O6Molecular weight488.70 g/mol434.35 g/mol434.35 g/mol470.60 g/molNo. H-bond acceptor511116No. H-bond donors4772Molar Refractivity139.24104.19104.19127.49TPSA97.99 Å^2^190.28 Å^2^190.28 Å^2^96.36 Å^2^**Lipophilicity**Log *P*~o/w~ (iLOGP)2.951.771.863.24Log *P*~o/w~ (XLOGP3)5.700.430.983.83Log *P*~o/w~ (WLOGP)5.030.100.103.35Log *P*~o/w~ (MLOGP)4.14−2.06−2.062.75Log *P*~o/w~ (SILICOS-IT)3.96−0.100.063.93Consensus Log *P*~o/w~4.360.030.193.42**Pharmacokinetics**GI absorptionHighLowLowHighBBB permeantNoNoNoNoP-gp substrateYesNoNoYesCYP1A2 inhibitorNoNoNoNoCYP2C19 inhibitorNoNoNoNoCYP2C9 inhibitorNoNoNoNoCYP2D6 inhibitorNoNoNoNoCYP3A4 inhibitorNoNoNoNoLog *K*~p~ (skin permeation)- 5.23 cm/s−8.64 cm/s−8.25 cm/s−6.45 cm/s**Water Solubility**Log *S* (ESOL)−6.33−2.99−3.27−4.97Solubility2.29e-4 mg/ml;\
4.69e-7 mol/l4.47e-01 mg/ml; 1.03e-03 mol/l2.34e-01 mg/ml; 5.39e-04 mol/l5.01e-03 mg/ml; 1.07e-05 mol/lClassPoorly solubleSolubleSolubleModerately solubleLog *S* (SILICOS-IT)−4.28−1.94−2.07−3.79Solubility2.59e-2 mg/ml; 5.31e-05 mol/l4.96e+00 mg/ml; 1.14e-02 mol/l3.71e+0 mg/ml; 8.55e-3 mol/l7.54e-02 mg/ml; 1.60e-04 mol/lClassModerately solubleSolubleSolubleSoluble**Medicinal Chemistry**LeadlikenessNo; 2 violations: MW \> 350, XLOGP3\>3.5No; 1 violation: MW \> 350No; 1 violation: MW \> 350No; 2 violations: MW \> 350, XLOGP3\>3.5Bioavailability Score0.560.170.170.55PAINS0 alert1 alert: catechol_A1 alert: catechol_A0 alertSynthetic accessibility6.565.055.046.83

3.4. Toxicity pattern analysis of top drug candidates {#sec3.4}
-----------------------------------------------------

Prediction of various toxicity endpoints such as acute toxicity, hepatotoxicity, cytotoxicity, carcinogenicity, mutagenicity, immunotoxicity, adverse outcomes (Tox21) pathways and toxicity targets were analysed ([Table 4](#tbl4){ref-type="table"} ). Results revealed that guajaverin and avicularin fell in the category of toxicity class 5, while the predicted toxicity group for Asiatic acid and withaferin were 4 and 2 respectively (the lower the class the higher the toxicity). Estimated LD50 for asiatic acid, avicularin, guajaverin and withaferin were 2000, 5000, 5000 and 7 mg/kg respectively. The toxicity radar in [Fig. 5](#fig5){ref-type="fig"} illustrates the confidence of positive toxicity results compared to the average of its class. None of the compounds showed any undesired effects such as tumorigenicity, mutagenicity, irritating, or reproductive effects. Withaferin, however, was found to be relatively toxic among the four candidates, with considerable cytotoxicity and immunotoxicity ([Fig. 5](#fig5){ref-type="fig"}).Table 4Toxicity model reports of the top four drug candidates.Table 4ClassificationTargetPrediction and ProbabilityAsiatic AcidAviculerinGuajaverinWithaferinOrgan toxicityHepatotoxicityInactive (0.91)Inactive (0.80)Inactive (0.80)Inactive (0.93)Toxicity end pointsCarcinogenicityInactive (0.70)Inactive (0.79)Inactive (0.79)Inactive (0.55)Toxicity end pointsImmunotoxicityActive (0.77)Active (0.68)Active (0.93)Active (0.99)Toxicity end pointsMutagenicityInactive (0.81)Inactive (0.73)Inactive (0.79)Inactive (0.79)Toxicity end pointsCytotoxicityInactive (0.73)Inactive (0.72)Inactive (0.69)Active (0.87)Tox21-Nuclear receptor signalling pathwaysAryl hydrocarbon Receptor (AhR)Inactive (0.99)Inactive (0.85)Inactive (0.90)Inactive (0.98)Tox21-Nuclear receptor signalling pathwaysAndrogen Receptor (AR)Inactive (0.59)Inactive (0.92)Inactive (0.96)Inactive (0.63)Tox21-Nuclear receptor signalling pathwaysAndrogen Receptor Ligand Binding Domain (AR-LBD)Inactive (0.51)Inactive (0.98)Inactive (0.97)Inactive (0.54)Tox21-Nuclear receptor signalling pathwaysAromataseInactive (0.91)Inactive (0.98)Inactive (0.97)Inactive (0.80)Tox21-Nuclear receptor signalling pathwaysEstrogen Receptor Alpha (ER)Inactive (0.73)Inactive (0.85)Inactive (0.92)Inactive (0.60)Tox21-Nuclear receptor signalling pathwaysEstrogen Receptor Ligand Binding Domain (ER-LBD)Inactive (0.97)Inactive (0.99)Inactive (0.99)Inactive (0.98)Tox21-Nuclear receptor signalling pathwaysPeroxisome Proliferator Activated Receptor Gamma (PPAR-γ)Inactive (0.97)Inactive (0.93)Inactive (0.94)Inactive (0.91)Tox21-Stress response pathwaysNuclear factor (erythroid-derived 2)-like 2/antioxidant responsive elementInactive (0.89)Inactive (0.91)Inactive (0.94)Inactive (0.86)Tox21-Stress response pathwaysHeat shock factor response element (HSE)Inactive (0.89)Inactive (0.91)Inactive (0.94)Inactive (0.86)Tox21-Stress response pathwaysMitochondrial Membrane Potential (MMP)Inactive (0.85)Inactive (0.89)Inactive (0.89)Inactive (0.80)Tox21-Stress response pathwaysPhosphoprotein (Tumor Supressor) p53Inactive (0.93)Active (0.55)Inactive (0.72)Inactive (0.75)Tox21-Stress response pathwaysATPase family AAA domain-containing protein 5 (ATAD5)Inactive (0.96)Inactive (0.96)Inactive (0.96)Inactive (0.94)Fig. 5Toxicity patterns of the top four drug candidates; A: Asiatic acid, B: Guajaverin, C: Avicularin, and D: Withaferin.Fig. 5

3.5. Prediction of drug targets and available drug molecules from DrugBank {#sec3.5}
--------------------------------------------------------------------------

Most of the target class belonged to enzymes, kinase proteins, oxidoreductases (i.e. aldose reductase, aldo-keto reductase), phosphatases and lyases (i.e. carbonic anhydrase) ([Fig. 6](#fig6){ref-type="fig"} and [Table 5](#tbl5){ref-type="table"} ). Ligand-based virtual screening was performed to predict biologically active small compounds against SARS-CoV-2 from DrugBank. Two approved drugs, Hydrocortisone (DB00741) and Dinoprost-tromethamine (DB01160) were found analogous to asiatic acid with prediction scores of 50.52 and 50.53, respectively. Moreover, results revealed the similarity of Mupirocin (DB00410) and Simvastatin (DB00641) with withaferin, with a high prediction score ([Table 6](#tbl6){ref-type="table"} ). The findings suggest that these could be potential drug candidates against SARS-CoV-2, thus requiring further experimental trials.Fig. 6Prediction of drug targets for asiatic acid (A), guajaverin (B), avicularin (C), and withaferin (D).Fig. 6Table 5Predicted drug targets for asiatic acid, guajaverin, aviculerin, and withaferin.Table 5Metab-olitesDrug TargetsCommon NameUniprot IDChEMBL IDTarget ClassProbabilityAsiatic AcidAldo-keto reductase family 1 member B10AKR1B10O60218CHEMBL5983Enzyme![](fx2_lrg.gif)Protein-tyrosine phosphatase 1BPTPN1P18031CHEMBL335Phosphatase![](fx3_lrg.gif)11-β-hydroxysteroid dehydrogenase 1HSD11B1P28845CHEMBL4235Enzyme![](fx4_lrg.gif)DNA polymerase betaPOLBP06746CHEMBL2392Enzyme![](fx5_lrg.gif)T-cell protein-tyrosine phosphatasePTPN2P17706CHEMBL3807Phosphatase![](fx6_lrg.gif)Phospholipase A2 group 1BPLA2G1BP04054CHEMBL4426Enzyme![](fx7_lrg.gif)Guajaverin & AviculerinAldose reductaseAKR1B1P15121CHEMBL1900Enzyme![](fx8_lrg.gif)Carbonic anhydrase IICA2P00918CHEMBL205Lyase![](fx9_lrg.gif)Carbonic anhydrase VIICA7P43166CHEMBL2326Lyase![](fx10_lrg.gif)Carbonic anhydrase XIICA12O43570CHEMBL3242Lyase![](fx11_lrg.gif)Carbonic anhydrase IVCA4P22748CHEMBL3729Lyase![](fx12_lrg.gif)NADPH oxidase 4NOX4Q9NPH5CHEMBL1250375Enzyme![](fx13_lrg.gif)Adrenergic receptor alpha-2ADRA2CP18825CHEMBL1916Family A G protein-coupled-receptor![](fx14_lrg.gif)AcetylcholinesteraseACHEP22303CHEMBL220Hydrolase![](fx15_lrg.gif)Quinone reductase 2NQO2P16083CHEMBL3959Enzyme![](fx16_lrg.gif)Ribosomal protein S6 kinase alpha 3RPS6KA3P51812CHEMBL2345Kinase![](fx17_lrg.gif)Neuromedin-U receptor 2NMUR2Q9GZQ4CHEMBL1075144Family A G protein-coupled receptor![](fx18_lrg.gif)WithaferinProtein kinase C alphaPRKCAP17252CHEMBL299Kinase![](fx19_lrg.gif)Cyclooxygenase-2PTGS2P35354CHEMBL230Oxidoreductase![](fx20_lrg.gif)Isoleucyl-tRNA synthetaseIARSP41252CHEMBL3235Enzyme![](fx21_lrg.gif)Protein kinase C deltaPRKCDQ05655CHEMBL2996Kinase![](fx22_lrg.gif)HMG-CoA reductaseHMGCRP04035CHEMBL402Oxidoreductase![](fx23_lrg.gif)Phosphodiesterase 4DPDE4DQ08499CHEMBL288Phosphodiesterase![](fx24_lrg.gif)Telomerase reverse transcriptaseTERTO14746CHEMBL2916Enzyme![](fx25_lrg.gif)Androgen ReceptorARP10275CHEMBL1871Nuclear receptor![](fx26_lrg.gif)Protein kinase C epsilonPRKCEQ02156CHEMBL3582Kinase![](fx27_lrg.gif)Proto-oncogene c-JUNJUNP05412CHEMBL4977Transcription factor![](fx28_lrg.gif)Protein-tyrosine phosphatase 1BPTPN1P18031CHEMBL335Phosphatase![](fx29_lrg.gif)Table 6Predicted bioactive molecules from DrugBank.Table 6MetabolitesDrug bank idNameScoreStatusAsiatic acidDB00741Hydrocortisone0.539ApprovedDB01160Dinoprost Tromethamine0.529ApprovedDB07886(11alpha,14beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione0.539ExperimentalDB07209(8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid0.510ExperimentalGuajaverinDB08995Diosmin0.280ApprovedDB02375Myricetin0.236ExperimentalWithaferinDB00410Mupirocin0.481ApprovedDB00641Simvastatin0.447ApprovedDB08224hexahydro-7-methyl-8-\[2-\[(2r,4r)-tetrahydro-4-hydroxy-6-oxo-2h-pyran-2-yl\]ethyl\]-1-naphthalenol0.501ExperimentalDB04775Reidispongiolide C0.479ExperimentalAvicularinDB08995Diosmin0.249ApprovedDB02375Myricetin0.210Experimental
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Excessive infection rates and mortality of SARS-CoV-2 led the researchers to concentrate immensely on developing strategies for combating infections caused by the pathogen \[[@bib69], [@bib70], [@bib71]\]. Regardless of this praiseworthy initiative, there are still no specific drugs or approved vaccines that could treat SARS-CoV-2 infected patients \[[@bib72],[@bib73]\]. Though some candidates are in the investigational stages, many of them raise controversial issues \[[@bib74],[@bib75]\]. Plant-derived natural products play a significant role by being a lead molecule in the development of drug candidates \[[@bib76]\]. Hence, in the present study, attempts were taken to evaluate some plant-derived metabolites as inhibitory agents of SARS-CoV-2 based on their binding affinities to the key proteins of the pathogen.

The contribution of computational biology has accelerated the pace of drug discovery \[[@bib77]\]. It is now used in the biopharmaceutical industry to discover and develop new lead compounds against many infectious pathogens \[[@bib77],[@bib78]\]. By this route, one can visualize the possibilities of binding of potential small molecules as ligands/inhibitors \[[@bib76]\]. Phytomolecules like Baicalein, Luteolin, Quercetin, and Kaempferol are potential antiviral agents against a wide range of important viruses including Dengue, HIV, H5N1 influenza A virus, Coxsackie virus, CHIKV, and Japanese encephalitis virus \[[@bib79]\]. Recent studies have focused on MPP inhibitors of SARS-CoV-2 i.e. alpha-ketoamide, Hydroxy, Remdesivir, Chloroquine and Favipiravir to evaluate their potency as drugs \[[@bib80],[@bib81]\]. Several *in silico* strategies were also adopted to screen putative drug candidates against SARS-CoV-2 \[[@bib82],[@bib83]\]. However, all these experiments used either main protease proteins or RNA-dependent RNA polymerase of SARS-CoV-2 as probable drug targets. In this study, we screened some natural metabolites against SARS-CoV-2 main proteases (6W63, 6LU7), Nsp9 (Non-structural protein-9) RNA binding protein (6W4B), spike receptor binding domain (6M0J), spike ecto-domain (6VYB), and HR2 domain (6LVN) using a molecular docking approach \[[@bib84], [@bib85], [@bib86]\]. The polyproteins of coronavirus are cleaved and transformed in mature non-structural proteins (Nsp) by proteases \[[@bib87]\]. As a putative component in the replication complex, Nsp9 may possibly have an RNA binding activity. Viral replication complexes are frequently membrane associated and Nsp9 helps in this case. The entry of coronavirus into host cells, on the contrary, is mediated by the transmembrane spike glycoprotein that forms homotrimers protruding from the viral surface. S protein comprises two functional subunits responsible for binding to the host cell receptor (S~1~) and fusion of the viral and cellular membranes (S). After the attachment of the receptor-binding subunit to the receptor, the HR1 and HR2 domains in the membrane fusion subunit interact with each other and form a six-helix bundle, and this conformational change results in a close apposition of the fusion peptide, leading to virus-cell membrane fusion \[[@bib88]\]. Thus, all of these proteins represent an attractive pharmacological target for SARS-CoV-2.

Results revealed that asiatic acid had highest binding affinity with SARS-CoV-2 main protease (−53.05 kcal/mol), Nsp9 RNA binding protein (−50.04 kcal/mol) and spike ecto-domain (60.68 kcal/mol) ([Fig. 2](#fig2){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}). Remarkably, four metabolites i.e. asiatic acid, avicularin, guajaverin and withaferin scored best for each six macromolecules and bound with minimum global binding energy ([Table 2](#tbl2){ref-type="table"} and Supplementary File 1). The scores of top candidates were either close or in some instances lower than alpha ketoamide, a positive control used in the present study ([Table 2](#tbl2){ref-type="table"}). Asiatic acid, a triterpenoid derivative from *Centella asiatica*, displayed antioxidative, anti-inflammatory, and protective properties against neurotoxicity induced by glutamate- or b-amyloid previously \[[@bib89]\]. Bian et al. also reported the inhibitory activities of asiatic acid and effectivity against fibroproliferative disorders (Keloids) through blocking the TGF-β/Smad pathway \[[@bib90]\]. Withanolides are nature-derived secondary metabolites produced in *Withania somnifera* via oxidation of steroids, which have medicinal value like anti-inflammation, anti-cancer, adaptogenic and anti-oxidant effects \[[@bib91]\]. Withaferin, a steroidal lactone from this group, suppresses HIV-1 LTR transcription and viral replication and also has a vital function to inhibit herpes simplex virus \[[@bib92],[@bib93]\]. It has anti-inflammatory properties and also shows neuro-protective activity against Aβ neurotoxicity \[[@bib94],[@bib95]\]. A molecular docking and simulation study revealed the vital function of withaferin to attenuate the neuraminidase of H1N1 influenza virus \[[@bib96]\].

Guajaverin (Quercetin 3-arabinopyranoside) and avicularin (quercetin- 3-O-α-L-arabinofuranoside) are the main bioactive components of guava leaves with hypoglycemic properties and inhibitory capacity against free fatty acid release \[[@bib97]\]. Previously, anti-plaque activity of guajaverine was attributed to its microbicidial activity against the growth of Strep \[[@bib38]\]. Avicularin, a flavonoid of plants, displayed diverse pharmacological properties such as anti-inflammatory effects and anti-infectious effects against pathogens \[[@bib98],[@bib99]\]. Lee et al. reported the effective anti-oxidant potentiality of Avicularin from *Lespedeza cuneata* \[[@bib100]\]. Researchers also identified hepatoprotective activity of avicularin extracted from the aerial parts of *Lespedeza cuneata* against lesions caused by t‐BHP in HepG2 cells \[[@bib101]\]. It has also been suggested to inhibit activation of ERK signaling pathways through LPS-stimulated overproduction of pro-inflammatory mediators and cytokine \[[@bib98]\]. Avicularin may suppress the inflammatory response, and causes apoptosis in human RA synovial cells through obstructing the activation of the MEK/NF-κB pathway, thus preventing rheumatoid arthritis (RA) *in vitro* \[[@bib102]\].

In the present study, we revealed the molecular interactions of top drug candidates with SARS-CoV-2 key proteins ([Fig. 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}). The binding sites for each ligand occupied the catalytic domain of SARS-CoV-2 main protease protein \[[@bib103]\]. Among the common binding residues, His41 and Cys145 form the catalytic dyad and act as a substrate recognition site \[[@bib103],[@bib104]\]. The top candidates were well fitted into the active pocket of MPP where several hydrophobic amino acid residues including Met49, Gly143, Cys145, Met165, Pro168, Ala191 compose a relatively hydrophobic environment, which may help to stabilize its conformation \[[@bib104]\]. The crucial binding sites of Nsp9 protein (39--73 region) are characterized by positively charged, glycine rich β-loops, which were proposed to be involved in RNA binding \[[@bib105]\]. Moreover, we targeted three distinct domains of SARS-CoV-2 spike protein, all of which play essential roles in the mechanism of viral entry into the host cell \[[@bib106]\]. The investigation may be useful to unravel the main drug target hotspot and medicinal chemistry of the investigational drugs currently under trials against SARS-CoV-2. ADME data, whether experimentally measured or computationally predicted, provide key insights into how a drug will ultimately be treated or accepted by the body. Hence, while a drug lead may exhibit phenomenal efficacy *in vitro*, poor ADME results often invariably terminate its development \[[@bib107]\]. Computational methods play a key role in anticipating potential ADME and toxicity problems and reducing the number of experiments that involve animal testing. Therefore, the topmost drug candidates were employed for ADME analysis to investigate their drug profiles. None of the metabolites, however, showed any undesirable consequences that could reduce their drug likeness properties. SARS-CoV-2 appears as a severe acute respiratory disease not a neuro disease \[[@bib108]\]. Thus, there is no need to permeate the blood brain barrier (BBB) for being an effective molecule against SARS-CoV-2. However, no BBB permeants were found among the top drug candidates. Most of the target class for the top drug candidates belonged to the categories of enzymes (e.g. oxidoreductases, hydrolase, phosphatases, lyases ([Table 5](#tbl5){ref-type="table"}). The major protease proteins (protein hydrolase) of SARS-CoV-2 thus can be a specific target for these natural metabolites. Guajaverin and avicularin are two isomers and derivatives of quercetin with a glycoside substituent in their chemical structure \[[@bib109],[@bib110]\]. The significant similarity between these two polar compounds in terms of structure, chemical formula, molar mass, and other physicochemical parameters ([Table 3](#tbl3){ref-type="table"}) may be responsible for covering the same targets by these two flavonoids ([Table 5](#tbl5){ref-type="table"}). The toxicity of drug impurities is closely related to their structure. Structure-activity relationships (SARs) have been widely used in Europe and the United States to predict toxicity by computer \[[@bib111]\]. The toxicity prediction results in the present study revealed negligible tumorigenic, mutagenic, irritating, or reproductive effects by the drug candidates, though withaferin was found to be comparatively toxic among the top four compounds. Despite having medicinal importance \[[@bib112],[@bib113]\], the ability of withaferin to inhibit cell growth and induce apoptosis in *in vitro* and *in vivo* models were reported \[[@bib114],[@bib115]\]. Moreover, dose dependent toxicity and other adverse effects such as elevation of liver enzymes, skin rash, fever etc. were observed by researchers \[[@bib115],[@bib116]\]. Our study also revealed the hepatotoxic and cytotoxic nature of withaferin through computational investigations.

However, drug similarity prediction identified two approved structural analogs of withaferin, Mupirocin (DB00410) and Simvastatin (DB00641) which could be alternative choices, and therefore require further *in vivo* investigations. Ligand-based virtual screening using asiatic acid predicted two other biologically active compounds, Hydrocortisone (DB00741) and Dinoprost-tromethamine (DB01160) from DrugBank. Interestingly, Hydrocortisone, a cortisone based drug, was previously used during the SARS-CoV-1 and MERS outbreak \[[@bib117]\]. Diosmin, on the contrary, is used as a supplementary drug and is found in various natural plants \[[@bib118]\]. Myricetin showed the potential to inhibit reverse transcriptase of the RLV and HIV viruses, while characterized as having antioxidative and prooxidative properties. It is also a potent anticarcinogen and antimutagen \[[@bib119]\]. The most significant finding of this study is Simvastatin, which can block downstream molecules (key factors in virus infectivity) and can control severe influenza and pneumonia through prevention of excess cytokine release \[[@bib120]\]. The results suggest that all these compounds could be potential drug candidates against SARS-CoV-2. The study may pave the way to develop effective medications and preventive measures against SARS-CoV-2 in the future.

5. Conclusion {#sec5}
=============

The results suggest that asiatic acid, avicularin, and guajaverin could be options to treat SARS-CoV-2 associated infections. Furthermore, two biologically active structural analogs from DrugBank i.e. Hydrocortisone and Simvastain may be effective and show potency against the viral pathogen. However, all the investigational drugs of SARS-CoV-2 are under strict regulation by the World Health Organization. Due to the encouraging results, we highly recommend further *in vivo* trials for the experimental validation of our findings.
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